| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
The specific molecular targets of WAY-116749 are not well characterized in the available literature. Preliminary results indicate that it possesses moderate antibacterial and antifungal properties against various strains, suggesting that it may target bacterial and fungal cellular components. The compound's structure includes a quinoxaline moiety, which is a pharmacophore found in various bioactive compounds with antimicrobial, anticancer, and anti-inflammatory activities. However, specific target identification requires further research.
|
|---|---|
| ln Vitro |
In vitro, WAY-116749 possesses moderate antibacterial and antifungal properties against various strains. Specific IC50 or MIC values are not detailed in the available literature. As a research compound, its activity is typically assessed using standard antimicrobial susceptibility testing methods. The compound may also be evaluated in cell-based assays for other activities, but specific data are not available. Further studies are needed to characterize its full in vitro activity profile.
|
| ln Vivo |
Specific in vivo data for WAY-116749 are not reported in the available literature. As a compound with moderate antimicrobial properties, it would have potential for in vivo studies in infection models. However, specific published in vivo protocols for this compound are not available. The compound is for research use only and not for human use. Further studies are needed to evaluate its in vivo efficacy and safety.
|
| Enzyme Assay |
The antibacterial and antifungal activities are assessed using standard broth microdilution or agar diffusion methods following CLSI guidelines. Bacterial and fungal strains are cultured in appropriate media and treated with serial dilutions of WAY-116749. The MIC is defined as the lowest concentration that inhibits visible growth. The compound is typically dissolved in DMSO and diluted in culture media. The compound may undergo oxidation reactions, particularly at the quinoxaline moiety.
|
| Cell Assay |
For cellular studies, bacterial and fungal strains are cultured in appropriate media. The compound is added at various concentrations, and growth is monitored by measuring optical density at 600 nm or by colony counting on agar plates. For cytotoxicity assessment, mammalian cell lines may be used, with cell viability measured by MTT or similar assays. The compound is typically stored at -80°C.
|
| Animal Protocol |
In vivo studies for WAY-116749 would be conducted in appropriate infection models. For antibacterial studies, mouse models of bacterial infection would be used. For antifungal studies, models of fungal infection would be employed. The compound would be administered via oral gavage or intraperitoneal injection. However, specific published protocols for this compound are not available. The compound is for research use only and not for human use.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for WAY-116749 are not reported. The compound has a molecular weight of 413.49 g/mol and a molecular formula of C₂₁H₂₃N₃O₄S. Pharmacokinetic studies would be required to determine parameters such as half-life, Cmax, oral bioavailability, and tissue distribution in animal models. The compound should be stored at -80°C.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for WAY-116749 are not reported. As a research compound, comprehensive toxicology studies including acute, subchronic, and genotoxicity assessments have not been reported. The compound is for research use only and not for human use. Standard safety precautions should be taken when handling, and the compound should be used in a controlled laboratory environment.
|
| Additional Infomation |
WAY-116749 is a research compound with moderate antibacterial and antifungal properties. Molecular formula: C₂₁H₂₃N₃O₄S, MW: 413.49. For research use only, not for human use. No clinical trials or regulatory approvals exist.
|
| Molecular Formula |
C21H23N3O4S
|
|---|---|
| Molecular Weight |
413.490023851395
|
| Exact Mass |
413.14
|
| CAS # |
380872-69-5
|
| PubChem CID |
2873796
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
645
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SECCSMLYJIENJQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H23N3O4S/c1-2-28-21(27)18-12-7-3-6-10-16(12)29-20(18)24-17(25)11-15-19(26)23-14-9-5-4-8-13(14)22-15/h4-5,8-9,15,22H,2-3,6-7,10-11H2,1H3,(H,23,26)(H,24,25)
|
| Chemical Name |
ethyl 2-[[2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)acetyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4184 mL | 12.0922 mL | 24.1844 mL | |
| 5 mM | 0.4837 mL | 2.4184 mL | 4.8369 mL | |
| 10 mM | 0.2418 mL | 1.2092 mL | 2.4184 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
